Anti-Gr1 antibodies, which reduced both Gr1+CD11b+Ly6G+Ly6C− granulocytic myeloid cells (neutrophils) and Gr1+CD11b+Ly6G−Ly6C+ monocytic myeloid cells, were administered to mice bearing non-fluorescent 4T1 tumor three times through intraperitoneal injection. This evidence concerns the gene ITGAM and neoplasm.